Compare Hyatt Hotels Corporation (H) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs GeneDx Holdings Corp — how do they compare? Hyatt Hotels Corporation trades at $161.02 (market cap $15.02B), while GeneDx Holdings Corp trades at $69.47 (market cap $2.02B). The key difference: Hyatt Hotels Corporation is far larger — about 7.4× GeneDx Holdings Corp's market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and GeneDx Holdings Corp for 19 Days on average.
| H | WGS | |
|---|---|---|
Market Cap | $15.02B | $2.02B |
Volume | 842,340 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $167.51 |
52-Week Low | $135.42 | $34.51 |
Typical Hold Time | 148 Days | 19 Days |
Enterprise Value | $18.93B | $2.05B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $160.27, up 1.99% with recent earnings beats but faces bearish technical signals. The stock shows mixed fundamentals with a high P/E of 196.83 and modest net income margin of 1.1%, though revenue growth to $7.10B in 2025 and strategic collaborations with Delta Air Lines highlight expansion efforts. Analyst consensus is moderately bullish with a $197.77 price target, but negative cash flow trends and elevated debt levels present challenges.
Outlook remains cautious due to valuation concerns and operational headwinds, though long-term growth initiatives offer potential upside. Key risks include profit margin volatility, high leverage, and competitive pressure. Investors should weigh analyst optimism against fundamental weaknesses before positioning.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
